PLATINOUS CHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	2Cl.Pt
Molecular Weight	265.99
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Cl-].[Cl-].[Pt++]

InChI

InChIKey=CLSUSRZJUQMOHH-UHFFFAOYSA-L

InChI=1S/2ClH.Pt/h2*1H;/q;;+2/p-2

HIDE SMILES / InChI

Molecular Formula	Pt
Molecular Weight	195.084
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24435208https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018057s083lbl.pdfftp://ftp.nrg.eu/pub/www/nrg/nrglib/2004/immobilisation_of_iodine.pdf
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00515 | https://www.ncbi.nlm.nih.gov/pubmed/27736024 | https://www.ncbi.nlm.nih.gov/pubmed/25159039

There is no available sources on the medical use of platinum iodide. The salt is insoluble.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA 278 Target ID: CHEMBL2311221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27736024	Crosslinking Agent 81

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2578
Unknown 2578
Metastatic testicular tumors 4 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018057s083lbl.pdf	Primary	Approved 8429	CISPLATIN Approved Use Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. Launch Date 2.82873594E11
Metastatic ovarian tumors 4 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018057s083lbl.pdf	Primary	Approved 8429	CISPLATIN Approved Use Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. Launch Date 2.82873594E11
Advanced bladder cancer 4 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018057s083lbl.pdf	Primary	Approved 8429	CISPLATIN Approved Use Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. Launch Date 2.82873594E11
Non-small cell lung cancer 206 Sources: https://clinicaltrials.gov/ct2/show/NCT00686322	Primary	Phase IV 63	CISPLATIN Approved Use Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. Launch Date 2.82873594E11

PubMed

Title	Date	PubMed
Platinum-catalyzed one-pot alkenylation of aldehydes using alkynes and triethylsilane: dual catalysis by platinum(II) chloride.	2013 Nov 1	24147871
Synthesis of tetracyclic chromenones via platinum(II) chloride catalysed cascade cyclization of enediyne-enones.	2014 Feb 28	24435208

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Dec 16 09:45:13 UTC 2023` Edited by `admin` on `Sat Dec 16 09:45:13 UTC 2023`
Record UNII	896SQ4TDHW
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PLATINOUS CHLORIDE

Common Name

English

PLATINUM(II) CHLORIDE

Systematic Name

English

PLATINOUS DICHLORIDE

Common Name

English

PLATINOUS CHLORIDE [HSDB]

Common Name

English

Platinous chloride [WHO-DD]

Common Name

English

PLATINUM CHLORIDE (PTCL2)

Common Name

English

PLATINOUS CHLORIDE [MI]

Common Name

English

PLATINUM DICHLORIDE

Systematic Name

English

PLATINUM(II) DICHLORIDE

Systematic Name

English

Code System Code Type Description

FDA UNII

896SQ4TDHW